NASDAQ:LNTH Lantheus (LNTH) Stock Price, News & Analysis $104.82 +1.09 (+1.05%) Closing price 04:00 PM EasternExtended Trading$103.50 -1.32 (-1.26%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Lantheus Stock (NASDAQ:LNTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lantheus alerts:Sign Up Key Stats Today's Range$102.84▼$105.8350-Day Range$92.89▼$110.9452-Week Range$47.25▼$111.86Volume473,876 shsAverage Volume945,239 shsMarket Capitalization$6.82 billionP/E Ratio25.26Dividend YieldN/APrice Target$110.43Consensus RatingModerate Buy Company Overview Lantheus Holdings, Inc. is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications. The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow. On the molecular imaging side, Lantheus markets Cardiolite® (technetium Tc-99m sestamibi) for myocardial perfusion imaging and Lexiscan® (regadenoson) for pharmacologic stress testing. In 2021, the company gained FDA approval and launched PYLARIFY® (piflufolastat F 18), a PET imaging agent for the detection of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer. Lantheus also maintains a robust pipeline of next-generation PET and therapeutic candidates in collaboration with academic and industry partners. Founded in 1956, Lantheus has expanded its reach through strategic acquisitions and global partnerships, serving hospitals, imaging centers and research institutions in more than 50 countries. The company operates a network of manufacturing facilities across North America and Europe, adhering to stringent quality and regulatory standards. Lantheus’ leadership team comprises experienced executives from the pharmaceutical and medical imaging industries, guiding the organization’s growth in precision diagnostics and targeted radiopharmaceutical therapies. Continuous investment in research and development underpins Lantheus’ mission to deliver innovative solutions that improve patient outcomes and drive value for healthcare providers worldwide.AI Generated. May Contain Errors. Read More Lantheus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreLNTH MarketRank™: Lantheus scored higher than 65% of companies evaluated by MarketBeat, and ranked 240th out of 837 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingModerate Buy Consensus RatingLantheus has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Lantheus is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageLantheus has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Lantheus' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth19.56% Earnings GrowthEarnings for Lantheus are expected to grow by 19.56% in the coming year, from $4.50 to $5.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lantheus is 25.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 45.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Lantheus is 25.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.90.Price to Book Value per Share RatioLantheus has a P/B Ratio of 6.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Lantheus' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.90% of the float of Lantheus has been sold short.Short Interest Ratio / Days to CoverLantheus has a short interest ratio ("days to cover") of 5.47.Change versus previous monthShort interest in Lantheus has recently increased by 4.67%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLantheus does not currently pay a dividend.Dividend GrowthLantheus does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.98 News SentimentLantheus has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Lantheus this week, compared to 10 articles on an average week.Search Interest6 people have searched for LNTH on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows7 people have added Lantheus to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lantheus insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Lantheus is held by insiders.Percentage Held by Institutions99.06% of the stock of Lantheus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lantheus' insider trading history. Receive LNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lantheus and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LNTH Stock News HeadlinesLantheus to Host Second Quarter 2026 Earnings Conference Call and Webcast on August 6, 2026, at 8:00 a.m. Eastern TimeJuly 23 at 9:00 AM | globenewswire.comLantheus Holdings to Host Second Quarter 2026 Conference Call and Webcast on August 6July 23 at 8:51 AM | quiverquant.comQBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.July 24 at 1:00 AM | Awesomely (Ad)Truist Financial Forecasts Strong Price Appreciation for Lantheus (NASDAQ:LNTH) StockJuly 18, 2026 | americanbankingnews.comRadioMedix Appoints Brian A. Markison to Board of DirectorsJuly 15, 2026 | globenewswire.com3 reasons to avoid LNTH and 1 stock to buy insteadJuly 14, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Pelthos Therapeutics (PTHS) and Lantheus (LNTH)June 30, 2026 | theglobeandmail.comFDA manufacturing issues delay Lantheus' tumor imaging kitJune 29, 2026 | msn.comSee More Headlines LNTH Stock Analysis - Frequently Asked Questions How have LNTH shares performed this year? Lantheus' stock was trading at $66.55 at the beginning of the year. Since then, LNTH shares have increased by 57.7% and is now trading at $104.9750. How were Lantheus' earnings last quarter? Lantheus Holdings, Inc. (NASDAQ:LNTH) issued its quarterly earnings data on Thursday, May, 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.25 by $0.21. The firm's revenue was up 1.2% compared to the same quarter last year. Read the conference call transcript. When did Lantheus IPO? Lantheus (LNTH) raised $103 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 10,833,334 shares at a price of $8.50-$10.50 per share. Citigroup, Jefferies, RBC Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. Who are Lantheus' major shareholders? Lantheus' top institutional shareholders include Reinhart Partners LLC. (2.46%), Assenagon Asset Management S.A. (1.10%), Handelsbanken Fonder AB (0.04%) and GAMMA Investing LLC (0.01%). Insiders that own company stock include Lantheus Alpha Therapy, Llc, Farallon Partners L L C/Ca, Rajiv A Patel, Mary Anne Heino, Robert J Jr Marshall, Paul Blanchfield, Daniel Niedzwiecki, Andrea Sabens, James H Thrall, Heinz Christoph Maeusli, Gerard Ber and Gary J Pruden. View institutional ownership trends. How do I buy shares of Lantheus? Shares of LNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lantheus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lantheus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings5/07/2026Today7/24/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 LNTH's financial health is in the Green zone, according to TradeSmith. LNTH has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LNTH CIK1521036 Webwww.lantheus.com Phone(978) 671-8001Fax978-671-8860Employees1,193Year FoundedN/APrice Target and Rating Average Price Target for Lantheus$110.43 High Price Target$129.00 Low Price Target$80.00 Potential Upside/Downside+5.4%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$4.15 Trailing P/E Ratio25.26 Forward P/E Ratio23.29 P/E GrowthN/ANet Income$233.56 million Net Margins18.05% Pretax Margin24.17% Return on Equity29.32% Return on Assets15.00% Debt Debt-to-Equity Ratio0.47 Current Ratio2.83 Quick Ratio2.64 Sales & Book Value Annual Sales$1.55 billion Price / Sales4.41 Cash Flow$6.40 per share Price / Cash Flow16.38 Book Value$16.43 per share Price / Book6.38Miscellaneous Outstanding Shares65,106,000Free Float63,999,000Market Cap$6.82 billion OptionableOptionable Beta-0.06 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:LNTH) was last updated on 7/24/2026 by MarketBeat.com Staff. From Our PartnersTrump’s emergency dollar resetBloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...Porter & Company | SponsoredHave you seen Elon’s new “supercurrency”? (It affects you)Elon Musk just became the world's first trillionaire following the biggest IPO in history, giving him access t...StocksToTrade | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThis tiny piece of glass could be bigger than GPUsA tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...Brownstone Research | SponsoredAugust 6 could be a BIG day for one AI companyOne AI company's revenue has surged 757 percent in the past year, earning it an A rating from Louis Navellier'...InvestorPlace | SponsoredThe number they’re trying to hide from youThe 10-year Treasury yield is nearing 4.4 percent, a level analyst Garrett Goggin says could force the Federal...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantheus Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantheus With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
